mProX™ Human BTK Stable Cell Line

Product Information

Target Protein

BTK

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

AML; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cardiovascular Research; Reproductive Research

Related Diseases

Agammaglobulinemia, X-Linked and Isolated Growth Hormone Deficiency, Type Iii, With Agammaglobulinemia. Among its related pathways are MIF Mediated Glucocorticoid Regulation and MyD88 dependent cascade initiated on endosome.

Gene ID

695

UniProt ID

Q06187

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Humans have a tyrosine kinase called bruton's tyrosine kinase, or tyrosine-protein kinase BTK, which is encoded by the BTK gene. Because it is essential for the receptor to send signals once immunoglobulin heavy chain rearrangement is complete, BTK is important for the formation of B cells. Additionally, it contributes to the activation of mast cells via the high-affinity IgE receptor. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is bound by the PH domain of Btk. PIP3 binding causes Btk to phosphorylate phospholipase C, which then breaks down PIP2, a phosphatidylinositol, into two second messengers: diacylglycerol (DAG) and inositol triphosphate (IP3). These messengers subsequently influence the function of proteins downstream during B-cell signaling. The customized BTK stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Helen

The BTK cell line was easy to use, and the customer service team was responsive and helpful. Highly recommended! Nov 17 2022

chat Verified Customer

chat Jessica

The technical support team was knowledgeable and provided prompt assistance whenever we had questions. I am extremely satisfied with this BTK overexpression cell line and the overall experience. May 14 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 AML cell lines express constitutively active BTK, but are insensitive to ibrutinib.

Microarray gene expression analysis was used to evaluate the expression of BTK mRNA in primary AML cells. Using immunoblotting, the expression of BTK and pBTK-Y223 in AML cell lines was ascertained.

Ref: Rotin, Lianne E., et al. "Ibrutinib synergizes with poly (ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism." Oncotarget 7.3 (2016): 2765.

Pubmed: 26624983

DOI: 10.18632/oncotarget.6409

Research Highlights

Bruton's tyrosine kinase (BTK) has become a viable target for therapeutic intervention in a number of diseases, including autoimmune disorders affecting B lymphocytes and hematopoietic cancers.
Liang, Chengyuan, et al. "The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review." European journal of medicinal chemistry 151 (2018): 315-326.
Pubmed: 29631132 DOI: 10.1016/j.ejmech.2018.03.062

Because it is necessary for B-lineage cells to differentiate and survive, the cytoplasmic protein-tyrosine kinase BTK is an appropriate target for medication.
Estupiñán, H. Yesid, et al. "Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects." Frontiers in Cell and Developmental Biology 9 (2021): 630942.
Pubmed: 33777941 DOI: 10.3389/fcell.2021.630942